Sanofi-Genzyme BioVentures (SGBV) is the corporate venture capital arm of Sanofi. SGBV invests in early stage companies with promising new products that may be future Sanofi pipeline candidates as well as integrated care opportunities. Today, SGBV has assembled a portfolio of direct equity investments in a variety of promising innovative life-science companies.

SGBV is an important component of Sanofi’s broader global strategy to invigorate external innovation.